{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:25:20Z","timestamp":1774675520831,"version":"3.50.1"},"reference-count":64,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2021.1478","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T12:13:15Z","timestamp":1633608795000},"source":"Crossref","is-referenced-by-count":8,"title":["Endothelial dysfunction and COVID\u201119 (Review)"],"prefix":"10.3892","volume":"15","author":[{"given":"Jalil","family":"Daher","sequence":"first","affiliation":[{"name":"Department of Biology, Faculty of Arts and Sciences, University of Balamand, Tripoli PO Box 100, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"key20220302134853_b1-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/HYPERTENSIONAHA.120.15291","article-title":"ACE2 (angiotensin-converting enzyme 2), COVID-19, and ACE inhibitor and Ang II (angiotensin II) receptor blocker use during the pandemic: The pediatric perspective","volume":"76","author":"South","year":"2020","journal-title":"Hypertension"},{"issue":"689360","key":"key20220302134853_b2-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/689360","article-title":"The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling","volume":"2014","author":"Pacurari","year":"2014","journal-title":"Int J Inflamm"},{"key":"key20220302134853_b3-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"key":"key20220302134853_b4-BR-15-6-01478","first-page":"1","article-title":"Other forms of oxidized LDL: Emerging functions","volume":"2","author":"Daher","year":"2020","journal-title":"World Acad Sci J"},{"key":"key20220302134853_b5-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood-2003-08-2974","article-title":"Direct evidence of leukocyte adhesion in arterioles by angiotensin II","volume":"104","author":"\u00c1lvarez","year":"2004","journal-title":"Blood"},{"key":"key20220302134853_b6-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/01.atv.19.7.1623","article-title":"Angiotensin induces inflammatory activation of human vascular smooth muscle cells","volume":"19","author":"Kranzh\u00f6fer","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20220302134853_b7-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/0014-5793(94)00531-1","article-title":"Activation of human peripheral monocytes by angiotensin II","volume":"347","author":"Hahn","year":"1994","journal-title":"FEBS Lett"},{"key":"key20220302134853_b8-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1161\/01.cir.100.11.1223","article-title":"Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis","volume":"100","author":"Tummala","year":"1999","journal-title":"Circulation"},{"key":"key20220302134853_b9-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1172\/JCI118623","article-title":"Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH\/NADPH oxidase activation. Contribution to alterations of vasomotor tone","volume":"97","author":"Rajagopalan","year":"1996","journal-title":"J Clin Invest"},{"key":"key20220302134853_b10-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/01.hjh.0000220402.53869.72","article-title":"Pathophysiological regulation of the AT1-receptor and implications for vascular disease","volume":"24 (Suppl 1)","author":"Wassmann","year":"2006","journal-title":"J Hypertens Suppl"},{"key":"key20220302134853_b11-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"H24","DOI":"10.1152\/ajpheart.00799.2009","article-title":"Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-\/- mice","volume":"298","author":"Judkins","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key20220302134853_b12-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.105.602532","article-title":"Endothelial nitric oxide synthase in vascular disease: From marvel to menace","volume":"113","author":"F\u00f6rstermann","year":"2006","journal-title":"Circulation"},{"key":"key20220302134853_b13-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5339\/gcsp.2013.34","article-title":"RAAS inhibition and mortality in hypertension","volume":"2013","author":"Ferrari","year":"2013","journal-title":"Glob Cardiol Sci Pract"},{"key":"key20220302134853_b14-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s11886-010-0140-7","article-title":"Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?","volume":"12","author":"Mansur","year":"2010","journal-title":"Curr Cardiol Rep"},{"key":"key20220302134853_b15-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic","volume":"16","author":"South","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"e21","key":"key20220302134853_b16-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"key20220302134853_b17-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"key20220302134853_b18-BR-15-6-01478","author":"Bean"},{"key":"key20220302134853_b19-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"key20220302134853_b20-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-CoV2: Should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"Kuster","year":"2020","journal-title":"Eur Heart J"},{"key":"key20220302134853_b21-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00467-011-2002-y","article-title":"The renin-angiotensin-aldosterone system in 2011: Role in hypertension and chronic kidney disease","volume":"27","author":"Sim\u00f5es","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"key20220302134853_b22-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1042\/CS20171550","article-title":"Fetal programming and the angiotensin-(1-7) axis: A review of the experimental and clinical data","volume":"133","author":"South","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"key20220302134853_b23-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.vph.2019.01.004","article-title":"Angiotensin II and vascular damage in hypertension: Role of oxidative stress and sympathetic activation","volume":"115","author":"Masi","year":"2019","journal-title":"Vascul Pharmacol"},{"key":"key20220302134853_b24-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"e00127","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"key20220302134853_b25-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"19840","key":"key20220302134853_b26-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1038\/srep19840","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"key20220302134853_b27-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"L178","DOI":"10.1152\/ajplung.00009.2008","article-title":"Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis","volume":"295","author":"Li","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"key20220302134853_b28-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"key20220302134853_b29-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1365-2362.2009.02153.x","article-title":"SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS","volume":"39","author":"Oudit","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"key20220302134853_b30-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"BRACE CORONA investigators: Effect of discontinuing vs. continuing angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: A Randomized Clinical Trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"key20220302134853_b31-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1136\/heartjnl-2020-317393","article-title":"Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people","volume":"106","author":"Hippisley-Cox","year":"2020","journal-title":"Heart"},{"key":"key20220302134853_b32-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1042\/CS20210182","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: Potential allies in the COVID-19 pandemic instead of a threat?","volume":"135","author":"Simko","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"key20220302134853_b33-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/jon.12770","article-title":"COVID-19 as a blood clotting disorder masquerading as a respiratory illness: a cerebrovascular perspective and therapeutic implications for stroke thrombectomy","volume":"30","author":"Janardhan","year":"2020","journal-title":"J Neuroimaging"},{"issue":"e38","key":"key20220302134853_b34-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with COVID-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"issue":"e60","key":"key20220302134853_b35-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2009787","article-title":"Large-vessel stroke as a presenting feature of COVID-19 in the young","volume":"382","author":"Oxley","year":"2020","journal-title":"N Engl J Med"},{"key":"key20220302134853_b36-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"key20220302134853_b37-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12975-020-00818-9","article-title":"COVID-19-related stroke","volume":"11","author":"Hess","year":"2020","journal-title":"Transl Stroke Res"},{"key":"key20220302134853_b38-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.mce.2008.11.003","article-title":"NADPH oxidases and angiotensin II receptor signaling","volume":"302","author":"Garrido","year":"2009","journal-title":"Mol Cell Endocrinol"},{"issue":"20","key":"key20220302134853_b39-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-016-0115-z","article-title":"Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome","volume":"14 (Suppl 1)","author":"El-Assaad","year":"2016","journal-title":"Thromb J"},{"issue":"E12","key":"key20220302134853_b40-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.3390\/antib5020012","article-title":"\u03b22GP1, anti-\u03b22GP1 antibodies and platelets: Key players in the antiphospholipid syndrome","volume":"5","author":"Ho","year":"2016","journal-title":"Antibodies (Basel)"},{"key":"key20220302134853_b41-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1515\/cclm-2020-0188","article-title":"Prominent changes in blood coagulation of patients with SARS-CoV-2 infection","volume":"58","author":"Han","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"key20220302134853_b42-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s12325-020-01399-7","article-title":"Dysfunctional coagulation in COVID-19: From cell to bedside","volume":"37","author":"Wang","year":"2020","journal-title":"Adv Ther"},{"issue":"963","key":"key20220302134853_b43-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05681-5","article-title":"Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study","volume":"20","author":"Gong","year":"2020","journal-title":"BMC Infect Dis"},{"key":"key20220302134853_b44-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"94","DOI":"10.5482\/ha-1134","article-title":"Coagulation and inflammation. Molecular insights and diagnostic implications","volume":"31","author":"Lipinski","year":"2011","journal-title":"Hamostaseologie"},{"issue":"3200","key":"key20220302134853_b45-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa583","article-title":"ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19","volume":"41","author":"Lupi","year":"2020","journal-title":"Eur Heart J"},{"issue":"111363","key":"key20220302134853_b46-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111363","article-title":"Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity","volume":"137","author":"Mehrabadi","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"key20220302134853_b47-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2119\/molmed.2009.00160","article-title":"ACE2 activation promotes antithrombotic activity","volume":"16","author":"Fraga-Silva","year":"2010","journal-title":"Mol Med"},{"issue":"120","key":"key20220302134853_b48-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"582","key":"key20220302134853_b49-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10050582","article-title":"Endothelial dysfunction and SARS-CoV-2 infection: Association and therapeutic strategies","volume":"10","author":"Deng","year":"2021","journal-title":"Pathogens"},{"key":"key20220302134853_b50-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/eurheartj\/ehaa623","article-title":"COVID-19 is, in the end, an endothelial disease","volume":"41","author":"Libby","year":"2020","journal-title":"Eur Heart J"},{"key":"key20220302134853_b51-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: A potential approach for coronavirus infection therapy?","volume":"134","author":"Batlle","year":"2020","journal-title":"Clin Sci (Lond)"},{"issue":"110337","key":"key20220302134853_b52-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110337","article-title":"Monoclonal antibody as a potential anti-COVID-19","volume":"129","author":"Jahanshahlu","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"8671713","key":"key20220302134853_b53-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8671713","article-title":"Endothelial dysfunction, inflammation, and oxidative stress in COVID-19-mechanisms and therapeutic targets","volume":"2021","author":"Fodor","year":"2021","journal-title":"Oxid Med Cell Longev"},{"issue":"293","key":"key20220302134853_b54-BR-15-6-01478","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00454-7","article-title":"Endothelial activation and dysfunction in COVID-19: From basic mechanisms to potential therapeutic approaches","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"key20220302134853_b55-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2011.02.044","article-title":"Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: A meta-analysis of randomised controlled trials","volume":"216","author":"Shahin","year":"2011","journal-title":"Atherosclerosis"},{"key":"key20220302134853_b56-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-Aldosterone system inhibitors and risk of covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"key20220302134853_b57-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality","volume":"324","author":"Fosb\u00f8l","year":"2020","journal-title":"JAMA"},{"key":"key20220302134853_b58-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1136\/heartjnl-2020-317336","article-title":"Treatment with ACE inhibitors or ARBs and risk of severe\/lethal COVID-19: A meta-analysis","volume":"106","author":"Flacco","year":"2020","journal-title":"Heart"},{"key":"key20220302134853_b59-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jamda.2020.06.018","article-title":"The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents","volume":"21","author":"De Spiegeleer","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"key20220302134853_b60-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/1741826711398430","article-title":"Effects of statins on coronary and peripheral endothelial function in humans: A systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Reriani","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"key20220302134853_b61-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2020.10.014","article-title":"Endothelial dysfunction in COVID-19: Current findings and therapeutic implications","volume":"314","author":"N\u00e4gele","year":"2020","journal-title":"Atherosclerosis"},{"key":"key20220302134853_b62-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s11239-020-02162-z","article-title":"The association between treatment with heparin and survival in patients with Covid-19","volume":"50","author":"Ayerbe","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"key20220302134853_b63-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"key20220302134853_b64-BR-15-6-01478","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"RECOVERY Collaborative Group: Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:49:03Z","timestamp":1646221743000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2021.1478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,7]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2021.1478","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"article-number":"102"}}